Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001962174 | SCV002128528 | pathogenic | Sphingolipid activator protein 1 deficiency | 2021-07-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PSAP protein in which other variant(s) (p.Thr217Ile) have been determined to be pathogenic (PMID: 2302219, 2320574; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with PSAP-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 5-6 of the PSAP gene. This variant would be expected to be in-frame, preserving the integrity of the reading frame. |